MedTrace Logo

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-09-15

Study results available
· View outcomes & findings →

Summary

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety, and pharmacokinetics of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression.

Conditions

  • Severe Postpartum Depression

Interventions

DRUG

SAGE-547

Administered as intravenous infusion.

DRUG

Placebo

Administered as intravenous infusion.

Sponsors & Collaborators

  • Supernus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen J Kanes, MD, PhD · Sage Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-15
Primary Completion
2016-06-22
Completion
2016-06-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614547 on ClinicalTrials.gov